Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.61 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.61 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MDH2 | P40926 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551347 | 1.00 | CFTR (0.67) | CFTRGPR84KDM4ECSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL30585295 | 0.98 | CFTR (0.65) | CFTRGPR84KDM4ECSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL29766716 | 0.98 | CFTR (0.65) | CFTRGPR84KDM4ECSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL9046989 | 0.98 | CFTR (0.65) | CFTRGPR84KDM4ECSNK2A2CSNK2B | |
| Pyrazine SCHEMBL10716045 | 0.92 | CFTR (0.58) | CFTRGPR84KDM4ECSNK2A2CSNK2B | |
| SCHEMBL6629595 | 0.91 | CFTR (0.61) | CFTRGPR84KDM4ECSNK2A2CSNK2B | |
| Water SCHEMBL29774742 | 0.89 | CFTR (0.59) | CFTRGPR84KDM4ECSNK2A2CSNK2B | |
| SCHEMBL64182 | 0.88 | GPR84 (0.77) | GPR84KDM4EGABRA1GABRB2NR4A2 | |
| Hydrochloric Acid SCHEMBL7437913 | 0.86 | GPR84 (0.74) | GPR84KDM4EGABRA1GABRB2NR4A2 | |
| SCHEMBL29272694 | 0.86 | GPR84 (0.74) | GPR84KDM4EGABRA1GABRB2NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4043439-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-03-12 | — | — | EP | claimed |
| EP-3464243-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-02-12 | — | — | EP | claimed |
| CN-118067873-A | Method for detecting impurities in moxifloxacin hydrochloride sodium chloride injection | 华夏生生药业(北京)有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-116606280-A | Fluoroquinolone compound and application thereof in preparation of antibacterial drugs | 广东工业大学 | 2023-08-18 | — | — | CN | claimed |
| CN-113735769-B | Quinolinone alkaloid derivative containing acylhydrazone structure at 3-position and preparation method and application thereof | 太原理工大学 | 2023-02-28 | — | — | CN | claimed |
| CN-113461612-B | Quinolone tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2022-10-14 | — | — | CN | claimed |
| CN-114539213-A | Fluoroquinolone compound and preparation method and application thereof | 广东工业大学 | 2022-05-27 | — | — | CN | claimed |
| US-11274081-B2 | Process for the synthesis of ivacaftor | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-03-15 | — | — | US | claimed |
| CN-113735769-A | Quinolinone alkaloid derivative containing acylhydrazone structure at 3-position and preparation method and application thereof | 太原理工大学 | 2021-12-03 | — | — | CN | claimed |
| CN-113461612-A | Quinolone tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2021-10-01 | — | — | CN | claimed |
| EP-0409081-A1 | Beta-Lactam Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1991-01-23 | — | — | EP | claimed |
| US-4859773-A | Preparation of 1,8-bridged 4-quinoline-3-carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1989-08-22 | — | — | US | claimed |
| US-4847375-A | Antibacterial 1,8-bridged 4-quinoline-3-carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-11 | — | — | US | claimed |
| US-4816451-A | Antibacterial 1,8-bridged 4-quinolonecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1989-03-28 | — | — | US | claimed |
| EP-0131839-B1 | QUINOLINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1989-02-01 | — | — | EP | claimed |
| US-4725595-A | 1,8-bridged 4-quinolone-3-carboxylic acid antibacterials | BAYER AKTIENGESELLSCHAFT (DE) | 1988-02-16 | — | — | US | claimed |
| CN-86104256-A | 1, the preparation method of 8-bridging 4-quinolone-3-carboxylic-acid | — | 1987-03-18 | — | — | CN | claimed |
| EP-0179239-A2 | 7-(Pyridinyl)-/-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid having antibacterial activity and preparation thereof | STERLING DRUG INC. (US) | 1986-04-30 | — | — | EP | claimed |
| EP-0131839-A1 | Quinoline antibacterial compounds | ABBOTT LABORATORIES (US) | 1985-01-23 | — | — | EP | claimed |
| US-4117136-A | ANTIBACTERIAL | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1978-09-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274081-B2 | Process for the synthesis of ivacaftor | IDO1, IDO2, SLC10A2 | CFTR 882/4885GPR84 441/4885KDM4E 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.